ODTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Odyssey Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$18.10+0.93 (+5.42%)
Close on Oct 19, 2026
- Market cap
- $548.01M
- P/E (TTM)
- –
- Dividend yield
- –
SEC filings
8 of Odyssey Therapeutics's most recent filings on SEC EDGAR
| Document | Form | Period | Filed | Source |
|---|---|---|---|---|
| Current report | 8-K | Oct 20, 2026 | Oct 20, 2026 | SEC EDGAR |
| Current report | 8-K | Sep 8, 2026 | Sep 9, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Jun 30, 2026 | Aug 6, 2026 | SEC EDGAR |
| Current report | 8-K | Aug 4, 2026 | Aug 4, 2026 | SEC EDGAR |
| Current report | 8-K | Jun 23, 2026 | Jun 23, 2026 | SEC EDGAR |
| Current report | 8-K | Jun 17, 2026 | Jun 17, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Mar 31, 2026 | Jun 17, 2026 | SEC EDGAR |
| Current report | 8-K | May 7, 2026 | May 11, 2026 | SEC EDGAR |